{"id":3336,"date":"2023-06-23T17:47:47","date_gmt":"2023-06-23T17:47:47","guid":{"rendered":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/?page_id=3336"},"modified":"2023-06-23T18:05:31","modified_gmt":"2023-06-23T18:05:31","slug":"rvo-2","status":"publish","type":"page","link":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/rvo-2\/","title":{"rendered":"RVO"},"content":{"rendered":"
\n\n\n\n\n\n
\n
\n
\n
\n\n
\"\"<\/picture><\/div>
<\/div><\/div>
\"\"<\/picture><\/div>
<\/div><\/div><\/div>
\n <\/svg>
Slide<\/div>
“I suddenly noticed blurry vision in one eye, and it got much worse over the course of a couple days. My doctor diagnosed me with retinal vein occlusion and said I can lose my vision permanently without frequent treatment.”<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
Slide<\/div>
Swelling in the eye (macular edema) secondary to retinal vein occlusion is the second most common cause of vision loss from retinal vascular disease, following diabetic retinopathy.<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div> <\/div>\n\n <\/div>\n <\/div>\n <\/div>\n
\"previous<\/div><\/div>
\"next<\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/ss3-loader><\/div><\/div>
<\/div><\/div><\/ss3-force-full-width><\/div>\n\n\n\n

WHAT IS RETINAL VEIN OCCLUSION (RVO)?<\/h2>\n\n\n\n
\n\n\n\n

The retina, the light-sensitive tissue in the back of the eye that helps process visual information, needs a constant supply of oxygen and nutrients delivered by blood vessels. If the veins in the eye become blocked (occluded), the oxygen supply gets compromised. This is known as retinal vein occlusion (RVO) and can lead to permanent vision loss if left untreated.<\/p>\n\n\n\n

RVO is characterized by where the blockage occurs. If the blockage occurs in the eye\u2019s main or central vein, it is called central retinal vein occlusion (CRVO). If one of the smaller veins emptying into the eye\u2019s main vein is occluded, it is called branch retinal vein occlusion (BRVO).<\/p>\n\n\n\n

\n\n\n\n\n\n\n\n
\n
\n
\n
\n\n
<\/div><\/div>
<\/div><\/div><\/div>
\n <\/svg>
Slide<\/div>
\"\"<\/picture><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
Slide<\/div>
\"\"<\/picture><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div> <\/div>\n\n <\/div>\n <\/div>\n <\/div>\n
\"previous<\/div><\/div>
\"next<\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/ss3-loader><\/div><\/div>
<\/div><\/div><\/ss3-force-full-width><\/div>\n\n
\n
\n
\n
\n\n
<\/div><\/div><\/div>
\n <\/svg>
Slide<\/div>
\"\"<\/picture>\"\"<\/picture><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
\"\"<\/picture>\"\"<\/picture><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div> <\/div>\n\n <\/div>\n <\/div>\n <\/div>\n <\/div><\/ss3-loader><\/div><\/div>
<\/div><\/div><\/ss3-force-full-width><\/div>\n\n\n\n

A blocked vein prevents adequate blood flow in the affected area. As a result, blood and fluid spill out into the retina. Patients with RVO are at risk for developing: <\/p>\n\n\n

\n
\n
\n
\n\n
<\/div><\/div><\/div>
\n <\/svg>
Kodiak_Illustrations_DME-01<\/div>
\"\"<\/picture>\"\"<\/picture><\/div><\/div><\/div><\/div><\/div>
\"\"<\/picture>\"\"<\/picture><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>

Tap the tiles to see more information<\/p>\n<\/div>

Tap the tiles to see more information<\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div> <\/div>\n\n <\/div>\n <\/div>\n <\/div>\n <\/div><\/ss3-loader><\/div><\/div>
<\/div><\/div><\/div><\/ss3-force-full-width><\/div>\n\n\n

CURRENT TREATMENT AND LIMITATIONS<\/h2>\n\n\n\n
\n\n\n\n

Injections in the eye that target the protein VEGF are the current standard of care for treating patients with RVO. These injections are burdensome because they need to be administered every month. Many patients are not able to adhere to this intense treatment schedule, putting them at risk of permanent vision loss.<\/p>\n\n\n\n\n\n

HOW KODIAK CAN HELP<\/h2>\n\n\n\n
\n\n\n\n

Kodiak\u2019s Antibody Biopolymer Conjugate (ABC)<\/ins> medicine in clinical development is designed to address these important challenges by doubling the treatment duration compared to standard of care.  Learn more.<\/a><\/p>\n\n\n\n

\n
\n

REFERENCES<\/h3>\n
\n
    \n
  1. Laouri et al. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011; 25:981-988. doi: 10.1038\/eye.2011.92<\/li>\n<\/ol>\n<\/div>\n <\/div>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":14,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-3336","page","type-page","status-publish","hentry"],"acf":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/pages\/3336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/comments?post=3336"}],"version-history":[{"count":3,"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/pages\/3336\/revisions"}],"predecessor-version":[{"id":3348,"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/pages\/3336\/revisions\/3348"}],"wp:attachment":[{"href":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/wp-json\/wp\/v2\/media?parent=3336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}